» Articles » PMID: 18276010

Definition of the Peptide Binding Motif Within DRB1*1401 Restricted Epitopes by Peptide Competition and Structural Modeling

Overview
Journal Mol Immunol
Date 2008 Feb 16
PMID 18276010
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

This study identified the peptide-binding motif of HLA-DRA/DRB1*1401 (DR1401). First, peptides containing DR1401 restricted epitopes were identified using tetramer-guided epitope mapping. Among these, an influenza B peptide was selected for the motif study. After confirming the binding register for this peptide using a set of arginine substitutions, binding affinities were determined for 33 peptides derived from this influenza B sequence with single amino acid substitutions. The DR1401 peptide-binding motif was deduced from the relative binding affinities of these peptides and confirmed by structural modeling. Pocket 1 demonstrated a preference for aliphatic anchor residues and methionine. Pocket 4 accommodated methionine and aliphatic residues, but also allowed some polar and charged amino acids. Pocket 6 preferred basic residues but also allowed some polar and aliphatic amino acids. Pocket 9 preferred aliphatic and aromatic amino acids and tolerated some polar residues but excluded all charged residues. Together these preferences define a distinct set of peptides that can be presented by DR1401. The resulting motif was used to verify T cell epitopes within the novel antigenic peptides identified by tetramer-guided epitope mapping and within peptides from published reports that contain putative DR1401 epitopes.

Citing Articles

Osteoclasts in the Inflammatory Arthritis: Implications for Pathologic Osteolysis.

Jung Y, Kang Y, Han S Immune Netw. 2019; 19(1):e2.

PMID: 30838157 PMC: 6399096. DOI: 10.4110/in.2019.19.e2.


PRBAM: a new tool to analyze the MHC class I and HLA-DR anchor motifs.

Mestre-Ferrer A, Scholz E, Humet-Alsius J, Alvarez I Immunology. 2018; 156(2):187-198.

PMID: 30408168 PMC: 6328992. DOI: 10.1111/imm.13020.


Immune recognition of citrullinated epitopes.

Nguyen H, James E Immunology. 2016; 149(2):131-8.

PMID: 27531825 PMC: 5011684. DOI: 10.1111/imm.12640.


In Silico Identification of Highly Conserved Epitopes of Influenza A H1N1, H2N2, H3N2, and H5N1 with Diagnostic and Vaccination Potential.

Munoz-Medina J, Sanchez-Vallejo C, Mendez-Tenorio A, Monroy-Munoz I, Angeles-Martinez J, Santos Coy-Arechavaleta A Biomed Res Int. 2015; 2015:813047.

PMID: 26346523 PMC: 4544958. DOI: 10.1155/2015/813047.


Immunodominant CD4+ T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein.

Chen L, Zanker D, Xiao K, Wu C, Zou Q, Chen W J Virol. 2014; 88(20):11760-73.

PMID: 25078703 PMC: 4178733. DOI: 10.1128/JVI.01631-14.


References
1.
Taylor G, Long H, Haigh T, Larsen M, Brooks J, Rickinson A . A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol. 2006; 177(6):3746-56. DOI: 10.4049/jimmunol.177.6.3746. View

2.
Stern L, Brown J, Jardetzky T, Gorga J, Urban R, Strominger J . Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994; 368(6468):215-21. DOI: 10.1038/368215a0. View

3.
NOVAK E, Liu A, Gebe J, Falk B, Nepom G, Koelle D . Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens. J Immunol. 2001; 166(11):6665-70. DOI: 10.4049/jimmunol.166.11.6665. View

4.
NOVAK E, Liu A, Nepom G, Kwok W . MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest. 1999; 104(12):R63-7. PMC: 480919. DOI: 10.1172/JCI8476. View

5.
Wucherpfennig K, Sette A, Southwood S, Oseroff C, Matsui M, Strominger J . Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med. 1994; 179(1):279-90. PMC: 2191316. DOI: 10.1084/jem.179.1.279. View